

PRESS RELEASE

1 October 2007



deltaDOT Ltd receives £3 million (\$6.05 million) from investors

London, UK, 1 October 2007.... deltaDOT Ltd, a developer of innovative molecular imaging technologies and products for bioscience research and biological production, today announced that it has received £3 million in a fourth and final tranche of funding from the investors in its last private equity financing round, following the continuing success of the business. This brings the total raised in the round to £6 million (\$12.1 million).

The funding round, which was announced in March 2006, comprised a syndicate of investors including FF&P Private Equity, Imperial Innovations, NPI Ventures, Sitka Health Fund VCT and London Technology Fund. FF&P Private Equity, the private equity division of Fleming Family & Partners (FF&P), acted as lead investor.

Anthony Baxter, CEO of deltaDOT said: "This funding highlights the success of deltaDOT and our recent corporate deals. We are already achieving our sales targets for Peregrine, our High Throughput Capillary Electrophoresis systems, and the funds raised will enable us to increase the production capacity for our Peregrine system. We will also develop our international sales and marketing function, particularly in the USA, which has already been expanded with a number of recent appointments to the board of directors and management team." The funding will also be used to continue to develop a number of other capillary and microfluidic products for molecular imaging, in particular the Osprey protein unfolding instrument which is set to improve on current thermal analysis of proteins currently employed by Differential Scanning Calorimetry (DSC) and Isothermal Titration Calorimetry (ITC).

deltaDOT's products make use of a novel biomolecule detection technique called Label Free Intrinsic Imaging (LFII™). This applies innovations in high-energy physics research to biochemical analysis. Unlike conventional techniques, the technology does not require target molecules to be labelled and enables superior data quantification, while reducing throughput times and operating costs.

deltaDOT recently announced that the company is playing a key role in a US Defence Advanced Research Projects Agency (DARPA) funded project to develop technology and processes that will reduce the time it takes to manufacture vaccines and protein therapeutics, to enhance the response to a wide range of biological threats. deltaDOT's Peregrine High Performance Capillary Electrophoresis and Osprey protein stability technology platforms are being used to analyse product quality in a cost-effective manner throughout product development, from the R&D to the quality control stages. The consortium of four companies, which is led by Xcellerex Inc (Marlborough, MA), received a total of US\$7.9 million from the Agency.

- ENDS -